Published: 2015-04-14 14:00:00 CEST

Resolutions passed by the Annual General Meeting of HKScan Corporation

HKScan Corporation      Stock Exchange Release           14 April 2015   at 3:00 pm

 

Resolutions passed by the Annual General Meeting of HKScan Corporation

The Annual General Meeting of HKScan Corporation, held on 14 April 2015 in Turku, adopted the parent company’s and consolidated financial statements and discharged the members of the Board of Directors and the CEO from liability for the year 2014.


Resolutions by the AGM based on proposals of the Board of Directors:


Dividend

The AGM resolved that dividend of EUR 0.10 and an additional dividend of EUR 0.39 be paid for each share for the year 2014. The dividend shall be paid to shareholders who are registered as shareholders in the Company’s shareholders’ register maintained by Euroclear Finland Ltd on the record date 16 April 2015. The payment date is 23 April 2015.


Election of the members of the Board of Directors and remuneration

The AGM resolved that the number of actual members of the Board of Directors to be six (6) and that two (2) deputy members will be elected to the Board of Directors.

The current Board members Niels Borup, Tero Hemmilä, Teija Andersen and Henrik Treschow were re-elected for a further term of office, and Mikko Nikula and Pirjo Väliaho were elected as new members of the Board of Directors. In addition, the current deputy Board member Per Nilsson was re-elected for a further term of office, and Marko Onnela was elected as new deputy member of the Board of Directors. At the organizational meeting after the AGM, the Board elected Mikko Nikula as Chairman and re-elected Niels Borup as Vice Chairman.

The AGM resolved that the amount of the annual remuneration payable to the members of the Board of Directors for the next term of office is as follows: EUR 22 100 to Board member, EUR 27 100 to Vice Chairman of the Board and EUR 54 250 to Chairman of the Board. An annual remuneration of EUR 7 450 is paid to deputy member of the Board of Directors. To Chairmen of the Board committees (Audit, Nomination, Compensation and Working Committee) an annual remuneration of EUR 5 000 is paid. In addition, a compensation of EUR 550 per a meeting is paid for all the Board members for each attended Board and Board committee meeting. Travel expenses will be compensated according to the Company’s travel policy.


Auditors

PricewaterhouseCoopers Oy, an audit firm chartered by the Central Chamber of Commerce, with Jouko Malinen, APA, as the main auditor was elected as the actual auditor until the close of the next Annual General Meeting. The remuneration of the auditor will be paid according to the auditor’s invoice accepted by the company.


Authorizations to the Board of Directors

The AGM gave the following two authorizations to the Board:

(1) The Board of Directors was authorized to decide on share issue as well as issue of option rights and other special rights entitling to shares, pursuant to Chapter 10 of the Companies Act as follows:

The shares issued under the authorization are new or those in the company’s possession Series A shares of the Company. Under the authorization, a maximum of 2 500 000 Series A shares, which corresponds to approximately 4.50 per cent of all of the shares in the Company and approximately 5.00 per cent of all the Series A shares in the Company, can be issued. The shares, option rights or other special rights entitling to shares can be issued in one or more tranches.

The Board of Directors may resolve upon issuing new Series A shares to the Company itself without consideration. However, the Company, together with its subsidiaries, cannot at any time own more than 10 per cent of all its registered shares.

The Board of Directors is authorized to resolve on all terms for the share issue and granting of the special rights entitling to shares. The Board of Directors is authorized to resolve on a directed share issue and issue of the special rights entitling to shares in deviation from the shareholders’ pre-emptive right. A directed share issue always requires a weighty economic reason for the Company and the authorization may not be utilized inconsistently with the principle of equal treatment of shareholders.

The authorization to issue new shares, options as well as other instruments entitling to shares was granted in order to enable the Board of Directors to decide flexibly on capital markets transactions that are beneficial for the Company, such as securing the financing needs of the Company or implementing acquisitions. In addition the authorization may be used in order to implement share based incentive arrangements directed to the management of the company and the Group companies.

The authorization is effective until 30 June 2016, and it revokes authorization granted on 10 April 2014 by the Annual General Meeting to the Board of Directors to resolve on an issue of shares, options as well as other instruments entitling to shares.


(2) The Board of Directors was authorized to decide on the purchase of the Company's own Series A shares and/or on the acceptance the Company's own Series A shares as pledge as follows:

The aggregate number of own Series A shares to be acquired and/or accepted as pledge shall not exceed 2 500 000 Series A shares in total, which corresponds to approximately 4.50 per cent of all of the shares in the Company and approximately 5.00 per cent of all the Series A shares in the Company. However, the Company together with its subsidiaries cannot at any moment own and/or hold as pledge more than 10 per cent of all the shares in the Company.

The Company’s own Series A shares may be purchased on the basis of the authorization only by using non-restricted equity which consequently reduces the amount of the funds available for distribution of profits. The Company’s own Series A shares may be purchased for a price quoted in public trading on the purchase day or for a price otherwise determined by the market.

The shares may be purchased under the authorization in order to develop the capital structure of the Company. In addition, the shares may be repurchased under the proposed authorization in order to finance or carry out acquisitions or other arrangements, as a part of incentive schemes or to be transferred for other purposes, or to be cancelled.

The Board of Directors shall resolve upon the method of purchase. Among other means, derivatives may be utilized in purchasing the shares. The shares may be purchased in a proportion other than that of the shares held by the shareholders (directed purchase). A directed purchase of the Company’s own shares always requires a weighty economic reason for the Company and the authorization may not be utilized inconsistently with the principle of equal treatment of shareholders.

The authorization is effective until 30 June 2016. It revokes the authorization granted on 10 April 2014 by the Annual General Meeting to the Board of Directors to acquire the company’s own Series A shares and/or to accept as pledge.


The minutes of the Annual General Meeting will be available (in Finnish) on www.hkscan.com no later than on 28 April 2015.


HKScan Corporation
Board of Directors


For further information:
Hannu Kottonen, CEO, HKScan Corporation. Kindly submit a call-back request to Marja-Leena Dahlskog, SVP Communications, firstname.surname@hkscan.com, tel. +358 10 570 2142


HKScan is the leading Nordic meat expert. We produce, market and sell high-quality, responsibly-produced pork, beef, poultry and lamb products, processed meats and convenience foods under strong brand names. Our customers are the retail, food service, industrial and export sectors, and our home markets comprise Finland, Sweden, Denmark and the Baltics. We export to close to 50 countries. In 2014, HKScan had net sales of approximately EUR 2.0 billion and some 7 700 employees.


DISTRIBUTION:
NASDAQ Helsinki
Main media
www.hkscan.com